Clinical Trial Update: Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Envafolimab as neoadjuvant immunotherapy for resectable locally advanced colorectal cancer with dMMR/MSI-H status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Envafolimab (envafolimab)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Status: UNKNOWN